Michael Caligiuri A MD


Michael Caligiuri A MD
ProfessorCollege of Medicinecaligiuri.1@osu.eduwebsite
521 James Cancer Hosp & Res Inst 300 W 10th Avenue Columbus Ohio 43210
Phone:614-293-7521Fax: (614) 293-3122
  • Administrative
  • Leukemia Research

General Research Interest

natural killer (NK) cell biology, Epstein Barr Virus (EBV), acute myeloid leukemia (AML)

Research Description

The Caligiuri laboratory has three areas of interest. First is to understand the development and normal role of the body's large granular lymphocytes called natural killer cells , and to exploit their properties in order to develop effective therapies against cancer and immune deficiency. The second is to understand why organ transplant patients with iatrogenic immune deficiency are highly susceptible to the development of lymphoma associated with the Epstein-Barr virus , and to develop a preventative strategy for this disorder. We use a SCID-human mouse model to explore novel therapies for the treatment of this and other types of lymphoma. The third area of focus is the molecular basis for the development of acute leukemia . We have mouse models of leukemia as well as the world's largest bank of frozen human leukemia cells to study the pathogenesis of acute leukemia, the prognostic significance of molecular defects in acute leukemia, and novel therapies for acute leukemia.

Current Publications

  • Caligiuri MA, Yu J, Deng Y, Chu J, Ren Y, Fan Z, Ji X, Mundy-Bosse B, Yuan S, Hughes T, Zhang J, Cheema B, Camardo AT, Xia Y, Wu LC, Wang LS, He X, Kinghorn AD, Li XThe Natural Product Phyllanthusmin C Enhances IFN-γ Production by Human NK Cells through Upregulation of TLR-Mediated NF-κB Signaling.J Immunol 193 9/15/2014
  • Mazzacurati L, Marzulli M, Reinhart B, Miyagawa Y, Goins WF, Li A, Kaur B, Caligiuri M, Cripe T, Chiocca N, Amankulor N, Cohen JB, Glorioso JC, Grandi PUse of miRNA response sequences to block off-target replication and increase the safety of an unattenuated, glioblastoma-targeted oncolytic HSV.Mol Ther in press 9/9/2014
  • Thorne AH, Meisen WH, Russell L, Yoo JY, Bolyard CM, Lathia JD, Rich J, Puduvalli VK, Mao H, Yu J, Caligiuri MA, Tridandapani S, Kaur BRole of Cysteine-rich 61 Protein (CCN1) in Macrophage-mediated Oncolytic Herpes Simplex Virus Clearance.Mol Ther 22 1678-87 9/1/2014
  • Wang Y, Liu Y, Tang F, Bernot KM, Schore R, Marcucci G, Caligiuri MA, Zheng P, Liu YEchinomycin protects mice against relapsed acute myeloid leukemia without adverse effect on hematopoietic stem cells.Blood 124 1127-35 8/14/2014
  • Becker H, Maharry K, Mrózek K, Volinia S, Eisfeld AK, Radmacher MD, Kohlschmidt J, Metzeler KH, Schwind S, Whitman SP, Mendler JH, Wu YZ, Nicolet D, Paschka P, Powell BL, Carter TH, Wetzler M, Kolitz JE, Carroll AJ, Baer MR, Caligiuri MA, Stone RM, Marcucci G, Bloomfield CDPrognostic gene mutations and distinct gene- and microRNA-expression signatures in acute myeloid leukemia with a sole trisomy 8.Leukemia 28 1754-8 8/1/2014
  • Yoo JY, Hurwitz BS, Bolyard C, Yu JG, Zhang J, Selvendiran K, Rath KS, He S, Bailey Z, Eaves D, Cripe TP, Parris DS, Caligiuri MA, Yu J, Old M, Kaur BBortezomib-induced unfolded protein response increases oncolytic HSV-1 replication resulting in synergistic antitumor effects.Clin Cancer Res 20 3787-98 7/15/2014
  • Hughes T, Briercheck EL, McClory S, Scoville SD, Keller K, Deng Y, Cole J, Harrison N, Mao C, Zhang J, Benson DM, Yu J, Caligiuri MA, Freud AG, Trotta RThe transcription Factor AHR prevents the differentiation of a stage 3 innate lymphoid cell subset to natural killer cells.Cell Rep 8 150-62 7/10/2014
  • Whitman SP, Kohlschmidt J, Maharry K, Volinia S, Mrózek K, Metzeler KH, Mendler JH, Eisfeld AK, Carroll AJ, Powell BL, Carter TH, Baer MR, Kolitz JE, Park IK, Stone RM, Caligiuri MA, Marcucci G, Bloomfield CD, Nicolet D, Schwind S, Becker HGAS6 expression identifies high-risk adult AML patients: potential implications for therapy.Leukemia 28 1252-8 6/1/2014
  • Freud AG, Yu J, Caligiuri MAHuman natural killer cell development in secondary lymphoid tissues.Semin Immunol 26 132-7 4/1/2014
  • Devine SM, Zhang X, Caligiuri MA, Hofmeister CC, Yu J, Chu J, Deng Y, Benson DM, He S, Hughes T, Zhang J, Peng Y, Mao H, Yi L, Ghoshal K, He XCS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma.Leukemia 28 917-27 4/1/2014
  • Kolitz JE, George SL, Benson DM Jr, Maharry K, Marcucci G, Vij R, Powell BL, Allen SL, Deangelo DJ, Shea TC, Stock W, Bakan CE, Hars V, Hoke E, Bloomfield CD, Caligiuri MA, Larson RA, Alliance for Clinical Trials in OncologyRecombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: results from Cancer and Leukemia Group B 19808.Cancer 120 1010-7 4/1/2014
  • Maharry K, Metzeler KH, Huang X, Kohlschmidt J, Mendler JH, Benito JM, Hickey C, Neviani P, Dorrance AM, Anghelina M, Khalife J, Tarighat SS, Volinia S, Whitman SP, Paschka P, Hoellerbauer P, Wu YZ, Han L, Bolon BN, Blum W, Mrózek K, Carroll AJ, Perrotti D, Andreeff M, Caligiuri MA, Konopleva M, Alachkar H, Santhanam R, Garzon R, Bloomfield CD, Marcucci GSPARC promotes leukemic cell growth and predicts acute myeloid leukemia outcome.J Clin Invest 124 1512-24 4/1/2014
  • Marcucci G, Yan P, Maharry K, Frankhouser D, Nicolet D, Metzeler KH, Kohlschmidt J, Mrózek K, Wu YZ, Bucci D, Curfman JP, Whitman SP, Eisfeld AK, Mendler JH, Schwind S, Becker H, Bär C, Carroll AJ, Baer MR, Wetzler M, Carter TH, Powell BL, Kolitz JE, Byrd JC, Plass C, Garzon R, Caligiuri MA, Stone RM, Volinia S, Bundschuh R, Bloomfield CDEpigenetics meets genetics in acute myeloid leukemia: clinical impact of a novel seven-gene score.J Clin Oncol 32 548-56 2/20/2014
  • Benson DM Jr, Caligiuri MAKiller immunoglobulin-like receptors and tumor immunity.Cancer Immunol Res 2 99-104 2/1/2014
  • Yu J, Freud AG, Caligiuri MALocation and cellular stages of natural killer cell development.Trends Immunol 34 573-82 12/1/2013
  • Bernot KM, Siebenaler RF, Whitman SP, Zorko NA, Marcucci GG, Santhanam R, Ahmed EH, Ngangana M, McConnell KK, Nemer JS, Brook DL, Kulp SK, Chen CS, Frankhouser D, Yan P, Bundschuh R, Zhang X, Dorrance AM, Dickerson KE, Jarjoura D, Blum W, Marcucci G, Caligiuri MAToward personalized therapy in AML: in vivo benefit of targeting aberrant epigenetics in MLL-PTD-associated AML.Leukemia 27 2379-82 12/1/2013
  • Bernot KM, Nemer JS, Santhanam R, Liu S, Zorko NA, Whitman SP, Dickerson KE, Zhang M, Yang X, McConnell KK, Ahmed EH, Muñoz MR, Siebenaler RF, Marcucci GG, Mundy-Bosse BL, Brook DL, Garman S, Dorrance AM, Zhang X, Zhang J, Lee RJ, Blum W, Caligiuri MA, Marcucci GEradicating acute myeloid leukemia in a Mll(PTD/wt):Flt3(ITD/wt) murine model: a path to novel therapeutic approaches for human disease.Blood 122 3778-83 11/28/2013
  • Walker CJ, Oaks JJ, Santhanam R, Neviani P, Harb JG, Ferenchak G, Ellis JJ, Landesman Y, Eisfeld AK, Gabrail NY, Smith CL, Caligiuri MA, Hokland P, Roy DC, Reid A, Milojkovic D, Goldman JM, Apperley J, Garzon R, Marcucci G, Shacham S, Kauffman MG, Perrotti DPreclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias.Blood 122 3034-44 10/24/2013
  • Dubovsky JA, Beckwith KA, Natarajan G, Woyach JA, Jaglowski S, Zhong Y, Hessler JD, Liu TM, Chang BY, Larkin KM, Stefanovski MR, Chappell DL, Frissora FW, Smith LL, Smucker KA, Flynn JM, Jones JA, Andritsos LA, Maddocks K, Lehman AM, Furman R, Sharman J, Mishra A, Caligiuri MA, Satoskar AR, Buggy JJ, Muthusamy N, Johnson AJ, Byrd JCIbrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes.Blood 122 2539-49 10/10/2013
  • Park IK, Trotta R, Yu J, Caligiuri MAAxl/Gas6 pathway positively regulates FLT3 activation in human natural killer cell development.Eur J Immunol 43 2750-5 10/1/2013
  • Harb JG, Neviani P, Chyla BJ, Ellis JJ, Ferenchak GJ, Oaks JJ, Walker CJ, Hokland P, Roy DC, Caligiuri MA, Marcucci G, Huettner CS, Perrotti DBcl-xL anti-apoptotic network is dispensable for development and maintenance of CML but is required for disease progression where it represents a new therapeutic target.Leukemia 27 1996-2005 10/1/2013
  • Metzeler KH, Caligiuri MA, Marcucci G, Bloomfield CD, Maharry K, Kohlschmidt J, Volinia S, Mrózek K, Becker H, Nicolet D, Whitman SP, Mendler JH, Schwind S, Eisfeld AK, Wu YZ, Powell BL, Carter TH, Wetzler M, Kolitz JE, Baer MR, Carroll AJ, Stone RMA stem cell-like gene expression signature associates with inferior outcomes and a distinct microRNA expression profile in adults with primary cytogenetically normal acute myeloid leukemia.Leukemia 27 2023-31 10/1/2013
  • Paisie CA, Eiring AM, Ma Y, Mao HC, Zhang B, Wunderlich M, May PC, Sun C, Saddoughi SA, Bielawski J, Blum W, Klisovic RB, Solt JA, Byrd JC, Volinia S, Cortes J, Huettner CS, Koschmieder S, Holyoake TL, Devine S, Caligiuri MA, Croce CM, Garzon R, Ogretmen B, Arlinghaus RB, Chen CS, Bittman R, Neviani P, Harb JG, Oaks JJ, Santhanam R, Walker CJ, Ellis JJ, Ferenchak G, Dorrance AM, Hokland P, Roy DC, Milojkovic D, Apperley J, Goldman JM, Reid A, Mulloy JC, Bhatia R, Marcucci G, Perrotti DPP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells.J Clin Invest 123 4144-57 10/1/2013
  • Walker CJ, Roof S, Oaks JJ, Santhanam R, Harb JG, Ferenchak G, Eisfeld AK, Van Brocklyn JR, Briesewitz R, Saddoughi SA, Nagata K, Bittman R, Caligiuri MA, Abdel-Wahab O, Levine R, Arlinghaus RB, Quintas-Cardama A, Goldman JM, Apperley J, Reid A, Milojkovic D, Ziolo MT, Marcucci G, Ogretmen B, Neviani P, Perrotti DAntagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies.Blood 122 1923-34 9/12/2013
  • Mendler JH, Maharry K, Becker H, Eisfeld AK, Senter L, Mrózek K, Kohlschmidt J, Metzeler KH, Schwind S, Whitman SP, Khalife J, Caligiuri MA, Klisovic RB, Moore JO, Carter TH, Marcucci G, Bloomfield CDIn rare acute myeloid leukemia patients harboring both RUNX1 and NPM1 mutations, RUNX1 mutations are unusual in structure and present in the germline.Haematologica 98 e92-4 8/1/2013
  • Maharry KS, Metzeler KH, Volinia S, Wu YZ, Mrózek K, Nicolet D, Kohlschmidt J, Whitman SP, Mendler JH, Schwind S, Becker H, Eisfeld AK, Carroll AJ, Powell BL, Kolitz JE, Garzon R, Caligiuri MA, Stone RM, Bloomfield CD, Marcucci GClinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patients.J Clin Oncol 31 2086-93 6/10/2013
  • Yu J, He S, Chu J, Wu LC, Mao H, Peng Y, Alvarez-Breckenridge CA, Hughes T, Wei M, Zhang J, Yuan S, Sandhu S, Vasu S, Benson DM Jr, Hofmeister CC, He X, Ghoshal K, Devine SM, Caligiuri MAMicroRNAs activate natural killer cells through Toll-like receptor signaling.Blood 121 4663-71 6/6/2013
  • Huang X, Schwind S, Yu B, Santhanam R, Wang H, Hoellerbauer P, Mims A, Klisovic R, Walker AR, Chan KK, Blum W, Perrotti D, Byrd JC, Bloomfield CD, Caligiuri MA, Lee RJ, Garzon R, Muthusamy N, Lee LJ, Marcucci GTargeted delivery of microRNA-29b by transferrin-conjugated anionic lipopolyplex nanoparticles: a novel therapeutic strategy in acute myeloid leukemia.Clin Cancer Res 19 2355-67 5/1/2013
  • Trotta R, Chen L, Costinean S, Josyula S, Mundy-Bosse BL, Ciarlariello D, Mao C, Briercheck EL, McConnell KK, Mishra A, Yu L, Croce CM, Caligiuri MAOverexpression of miR-155 causes expansion, arrest in terminal differentiation and functional activation of mouse natural killer cells.Blood 121 3126-34 4/18/2013
  • Alvarez-Breckenridge CA, Yu J, Caligiuri MA, Chiocca EAUncovering a novel mechanism whereby NK cells interfere with glioblastoma virotherapy.Oncoimmunology 2 e23658 4/1/2013
  • Mims A, Walker AR, Huang X, Sun J, Wang H, Santhanam R, Dorrance AM, Walker C, Hoellerbauer P, Tarighat SS, Chan KK, Klisovic RB, Perrotti D, Caligiuri MA, Byrd JC, Chen CS, James Lee L, Jacob S, Mrózek K, Bloomfield CD, Blum W, Garzon R, Schwind S, Marcucci GIncreased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: a novel epigenetic-targeting approach in acute myeloid leukemia.Leukemia 27 871-8 4/1/2013
  • Li Z, Herold T, He C, Chen J, Valk PJ, Chen P, Jurinovic V, Mansmann U, Radmacher MD, Maharry KS, Sun M, Yang X, Huang H, Jiang X, Sauerland MC, Büchner T, Hiddemann W, Elkahloun A, Neilly MB, Zhang Y, Larson RA, Le Beau MM, Caligiuri MA, Döhner K, Bullinger L, Liu PP, Delwel R, Marcucci G, Lowenberg B, Bloomfield CD, Rowley JD, Bohlander SKIdentification of a 24-gene prognostic signature that improves the European LeukemiaNet risk classification of acute myeloid leukemia: an international collaborative study.J Clin Oncol 31 1172-81 3/20/2013
  • Rafiq S, Butchar JP, Cheney C, Mo X, Trotta R, Caligiuri M, Jarjoura D, Tridandapani S, Muthusamy N, Byrd JCComparative assessment of clinically utilized CD20-directed antibodies in chronic lymphocytic leukemia cells reveals divergent NK cell, monocyte, and macrophage properties.J Immunol 190 2702-11 3/15/2013
  • Park IK, Mishra A, Chandler J, Whitman SP, Marcucci G, Caligiuri MAInhibition of the receptor tyrosine kinase Axl impedes activation of the FLT3 internal tandem duplication in human acute myeloid leukemia: implications for Axl as a potential therapeutic target.Blood 121 2064-73 3/14/2013
  • Li J, Xu C, Wang L, Zhou M, Jiang M, Zhou J, Caligiuri MA, Nervi C, Bloomfield CD, Marcucci G, Yu L, Li Y, Gao L, Luo X, Wang L, Gao X, Wang W, Sun J, Dou LEpigenetic silencing of microRNA-193a contributes to leukemogenesis in t(8;21) acute myeloid leukemia by activating the PTEN/PI3K signal pathway.Blood 121 499-509 1/17/2013
  • Edwards CG, Nicolet D, Mrózek K, Maharry K, Wu YZ, Paschka P, Eisfeld AK, Hoellerbauer P, Becker H, Metzeler KH, Curfman J, Kohlschmidt J, Prior TW, Kolitz JE, Blum W, Pettenati MJ, Dal Cin P, Carroll AJ, Caligiuri MA, Schwind S, Larson RA, Volinia S, Marcucci G, Bloomfield CD, Alliance for Clinical Trials in Oncologyinv(16)/t(16;16) acute myeloid leukemia with non-type A CBFB-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations.Blood 121 385-91 1/10/2013
  • Alachkar H, Maharry K, Nicolet D, Mrózek K, Walker A, Eiring AM, Whitman SP, Becker H, Perrotti D, Wu LC, Zhao X, Fehniger TA, Vij R, Byrd JC, Blum W, Lee LJ, Caligiuri MA, Bloomfield CD, Garzon R, Marcucci G, Hickey CJ, Schwind S, Radomska HS, Dorrance AM, Santhanam R, Mishra A, Wu YZLenalidomide-mediated enhanced translation of C/EBPα-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia.Blood 121 159-69 1/3/2013
  • Alachkar H, Santhanam R, Harb JG, Lucas DM, Caligiuri MA, Perrotti D, Byrd JC, Garzon R, Grever MR, Marcucci G, Oaks JJ, Hickey CJ, Pan L, Kinghorn ADSilvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155 expressions in acute myeloid leukemia.J Hematol Oncol 6 21 1/1/2013
  • Alvarez-Breckenridge CA, Yu J, Price R, Wojton J, Pradarelli J, Mao H, Wei M, Wang Y, He S, Hardcastle J, Fernandez SA, Kaur B, Lawler SE, Vivier E, Mandelboim O, Moretta A, Caligiuri MA, Chiocca EANK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors.Nat Med 18 1827-34 12/1/2012
  • Benson DM Jr, Hofmeister CC, Padmanabhan S, Suvannasankha A, Jagannath S, Abonour R, Bakan C, Andre P, Efebera Y, Tiollier J, Caligiuri MA, Farag SSA phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma.Blood 120 4324-33 11/22/2012

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 300 W. 10th Ave. Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu